Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

In re Pradaxa (Dabigatran Etexilate) Products Liability Litigation

United States District Court, S.D. Illinois

April 30, 2014

IN RE PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION. This Document Relates to: ALL CASES

CASE MANAGEMENT ORDER NUMBER 65 ADDRESSING MOTIONS CHALLENGING CERTAIN CONFIDENTIALITY DESIGNATIONS

DAVID R. HERNDON, Chief District Judge.

I. INTRODUCTION

This matter is before the Court on two motions filed by the Plaintiffs' Steering Committee ("PSC"): (1) motion challenging the confidentiality designations placed on certain deposition testimony by defendants Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. (collectively referred to herein as "BI") (Doc. 463) and (2) motion challenging the confidentiality designations placed on certain deposition exhibits by BI (Doc. 464). BI has responded to each motion (Doc. 472 and Doc. 471). For the reasons discussed herein the Court finds in favor of BI.[1] The motions to remove BI's confidentiality designations are therefore DENIED.

II. ANALYSIS

A. Applicable Standards

Pursuant to Federal Rule of Civil Procedure 26(c)(1), a court may "for good cause" issue a protective order requiring that "confidential research, development or commercial information" be revealed in a particular way. Fed.R.Civ.P. 26(c)(1)(G). The Court exercised this power by entering Amended CMO 2, which is designed to "protect[] the defendants' commercially sensitive information while fostering the truth seeking function of the discovery process" (Doc. 176 p. 8). The Court further explained in CMO 56 that to sustain a confidentiality designation under Amended CMO 2, BI must "demonstrate a particular need for protection" and offer "evidence that a clearly defined and serious injury will result" in the absence of the confidentiality protection (Doc. 397 p. 5).

In the instant case, BI bears the burden of establishing that its confidentiality designations are proper.

B. Confidentiality Designations - Deposition Testimony (Doc. 463)

In accord with Amended CMO 2, [2] the PSC challenges the confidentiality designations that BI has placed on certain deposition testimony. Specifically, the PSC challenges three sections of deposition testimony from two BI employees, Dr. Jeffrey Friedman and Dr. Janet Schnee. The PSC contends that the testimony in issue does not contain the type of sensitive and proprietary information that is entitled to the confidentiality protections allowed by Amended CMO 2 and asks the Court to order BI to remove the confidentiality designations it has placed on the same.

BI contends that the disputed confidentiality designations are appropriate for the following reasons:

• The testimony relates to BI's re-examination of the RE-LY trial[3]
• BI's business, legal, and regulatory strategy for seeking FDA approval, information that would be of considerable value to BI's competitors

After reviewing the disputed confidentiality designations, the Court finds that BI has met its burden of establishing good cause for the same. As to Dr. Schnee's testimony, the disputed excerpts relate to an ongoing scientific investigation by BI. The public release of that information could harm BI's scientific investigation. As to Dr. Friedman's testimony, the disputed excerpts relate to incomplete and/or ongoing scientific investigation. ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.